TABLE 4.

side effects, cause of interruption and treatment of switch

Adverse events	N° (% on total population)
Upper respiratory tract infections	2 (1.2%)
Cefalea	1 (0.6%)
Arthralgya	1 (0.6%)
Peri‐malleolar edema	1 (0.6%)
Diarrhea	1 (0.6%)
Death (not correlated to the treatment)	1 (0.6%)
Total	7 (4.2%)

Cause of interruption	N° (% on total population)
Primary inefficacy	6 (3.6%)
Peri‐malleolar edema	1 (0.6%)
Total	7 (4.2%)

Treatment of switch	N° (% on total population)
Cyclosporine	3 (1.8%)
Brodalumab	2 (1.2%)
Certolizumab Pegol	1 (0.6%)
None	1 (0.6%)
Total	7 (4.2%)